#### Supplemental material

# Anti-otomycotic Potential of Nanoparticles of *Moringa oleifera* Leaf Extract: An Integrated *In vitro*, *In silico* and Phase 0 Clinical Study

#### **Molecular Dynamics Simulation**

Desmond v. 2.2 software was used for performing MDS experiments [3–5]. This software applies the OPLS-2005 force field. Protein systems were built using the System Builder option, where the protein structure was checked for any missing hydrogens, the protonation states of the amino acid residues were set (pH = 7.4), and the co-crystalized water molecules were removed. Thereafter, the whole structure was embedded in an orthorhombic box of TIP3P water together with 0.15 M Na+ and Cl- ions in 20 Å solvent buffer. Afterward, the prepared systems were energy minimized and equilibrated for 10 ns. For proteinligand complexes, the top-scoring poses were used as a starting points for simulation. Desmond software automatically parameterizes inputted ligands during the system building step according to the OPLS force field. For simulations performed by NAMD [6], the protein structures were built and optimized by using the QwikMD toolkit of the VMD software. The parameters and topologies of the compounds (1 (S and R isomers), 2, 5-8, 11) were calculated either using the Charmm27 force field with the online software Ligand Reader and Modeler (http://www.charmm-gui. org/?doc=input/ligandrm, accessed on 16 April 2021) [7] or using the VMD plugin Force Field Toolkit (ffTK) (compounds 3, 4, 9, 10). Afterward, the generated parameters and topology files were loaded to VMD to readily read the protein-ligand complexes without errors and then conduct the simulation step.

### **Binding Free Energy Calculations**

Binding free energy calculations ( $\Delta G$ ) were performed using the free energy perturbation (FEP) method [7]. This method was described in detail in the recent article by Kim and coworkers [7]. Briefly, this method calculates the binding free energy  $\Delta G_{\text{binding}}$  according to the following equation:  $\Delta G_{\text{binding}} = \Delta G_{\text{Complex}} - \Delta G_{\text{Ligand}}$ . The value of each  $\Delta G$  is estimated from a separate simulation using NAMD software. All input files required for simulation by NAMD can be prepared

by using the online website Charmm-GUI (https://charmm-gui.org/?doc=input/afes.abinding, accessed on 18 May 2021). Subsequently, we can use these files in NAMD to produce the required simulations using the FEP calculation function in NAMD. The equilibration (5 ns long) was achieved in the NPT ensemble at 300 K and 1 atm (1.01325 bar) with Langevin piston pressure (for "Complex" and "Ligand") in the presence of the TIP3P water model. Then, 10 ns FEP simulations were performed for each compound, and the last 5 ns of the free energy values were measured for the final free energy values [7]. Finally, the generated trajectories were visualized and analyzed using VMD software.

Table S1. Compositions of different MME nanoformulations

Formulation codes	Moringa Extr	act Lecithin (%w/v)	Chitosan	Tween (%w/v)
	(%w/v)		(%w/v)	
MF1	1%	16%	7%	1%
MF2	1%	10%	21%	1%
MF3	1%	6%	35%	1%

**Table S2. Pre-treatment clinical characteristics** 

Parameters	Group I	Group II (control)	p-value	
Fungal swabs	100%	100%		
Erythema	70%	60%		
Scaling	30%	30%		
Weeping	30%	40%		
Discharge	80%	60%	0 6690	
pruritis	80%	70%	0.0050	
Pain	70%	70%		
Burning	50%	60%		
Tinnitus	40%	60%		
Pus	0	0		

Parameters	Group I	Group II (control)	p-value	
Positive Fungal swabs isolates	0	50%		
Erythema	20%	50%		
Scaling	10%	30%		
Weeping	0	20%		
Discharge	0	10%	0,0006	
pruritis	0	30%	0.0000	
Pain	0	4		
Burning	20%	50%		
Tinnitus	10%	40%		
Pus	0	0	1	

# **Table S3.** Clinical characteristics one week post-treatment

**Table S4.** Dereplicated compounds from Moringa ethanol extract using HR-LC-MS profiling

No	Compound	Formula	Exact	Ref
			mass	
1	4-Hydroxybenzoic acid; O-β-D-	C <sub>13</sub> H <sub>16</sub> O <sub>8</sub>	300.085	[32]
	Glucopyranoside			
2	2,4-dihydroxybenzaldehyde	C <sub>7</sub> H <sub>6</sub> O <sub>3</sub>	138.032	[33]
3	Moringyne	$C_{15}H_{20}O_7$	312.121	[34]
4	2-Hydroxyphenylacetic acid O-b-D-	C <sub>14</sub> H <sub>18</sub> O <sub>8</sub>	314.100	[35]
	glucoside			
5	4-O-(3'-o-alpha-D-Glucopyranosyl)-	C <sub>22</sub> H <sub>28</sub> O <sub>14</sub>	516.148	[36]
	caffeoyl quinic acid			
6	Kaempferol-3-O-alpha-rhamnoside-	C <sub>33</sub> H <sub>40</sub> O <sub>20</sub>	756.211	[37]
	7,4'-di-O-beta-glucoside			
7	3,4-dihydroxybenzoic acid	C <sub>7</sub> H <sub>6</sub> O <sub>4</sub>	154.027	[38]
8	Secothujene (Diplodialide B)	C <sub>10</sub> H <sub>16</sub> O <sub>3</sub>	184.110	[39]
9	Cucurbic acid	C <sub>12</sub> H <sub>20</sub> O <sub>3</sub>	212.141	[40]
10	12-hydroxyjasmonic acid	C <sub>12</sub> H <sub>18</sub> O <sub>4</sub>	226.121	[41]

11	Caffeoquinone	C <sub>9</sub> H <sub>6</sub> O <sub>4</sub>	178.027	[42]
12	2-Hydroxyhexadecanoic acid	C <sub>16</sub> H <sub>32</sub> O <sub>3</sub>	272.235	[43]
13	Plakolide A	C <sub>18</sub> H <sub>28</sub> O <sub>2</sub>	276.209	[43]
14	Emmotin A	C <sub>16</sub> H <sub>22</sub> O <sub>4</sub>	278.152	[44]
15	(chlorogenic acid)	C <sub>16</sub> H <sub>18</sub> O <sub>9</sub>	354.095	[45]
16	Rosmarinine	C <sub>18</sub> H <sub>27</sub> NO <sub>6</sub>	353.184	[46]
17	pectolinarin	C <sub>29</sub> H <sub>34</sub> O <sub>15</sub>	622.190	[47]
18	Niazinin A	C <sub>15</sub> H <sub>21</sub> NO <sub>6</sub> S	343.109	[48]
19	Niazimicin A	C <sub>16</sub> H <sub>23</sub> NO <sub>6</sub> S	357.125	[49]
20	Niaziminin B	C <sub>19</sub> H <sub>25</sub> NO <sub>7</sub> S	411.135	[48]
21	N-[(4-hydroxyphenyl)methyl]	C <sub>22</sub> H <sub>29</sub> NO <sub>9</sub> S	483.156	[35]
	ethoxycarbothioamide			
	4'-(tri-acetylrhamnoside			
22	Niazicinin A	C <sub>17</sub> H <sub>23</sub> NO <sub>8</sub>	369.142	[50]
23	Moringin (4-hydroxybenzyl-	C <sub>14</sub> H <sub>17</sub> NO <sub>5</sub> S	311.083	[51]
	isothiocyanate rhamnoside)			
24	4-Hydroxybenzyl-isothio-	C <sub>16</sub> H <sub>19</sub> NO <sub>6</sub> S	353.093	[52]
	cyanate-4"-acetylrhamnoside			
25	Niazirin	C <sub>14</sub> H <sub>17</sub> NO <sub>5</sub>	279.111	[53]
26	Niazirinin	C <sub>16</sub> H <sub>19</sub> NO <sub>6</sub>	321.121	[54]
27	Niazidin	$C_{15}H_{18}N_2O_6$	354.089	[55]
		S		

## References

1. Seeliger, D.; de Groot, B.L. Ligand docking and binding site analysis with PyMOL and Autodock/Vina.

2. Moy, F. J., Chanda, P. K., Chen, J. M., Cosmi, S., Edris, W., Skotnicki, J. S., ... & Powers, R. (1999). NMR solution structure of the catalytic fragment of human fibroblast collagenase complexed with a sulfonamide derivative of a hydroxamic acid compound. *Biochemistry*, *38*(22), 7085-7096.

Bowers, K.J.; Chow, D.E.; Xu, H.; Dror, R.O.; Eastwood, M.P.; Gregersen, B.A.; Klepeis, J.L.; Kolossvary, I.; Moraes, M.A.; Sacerdoti, F.D.; et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. In Proceedings of the SC'06: Proceedings of the 2006 ACM/IEEE Conference on Supercomputing, Tampa, FL, USA, 11–17 November 2006; IEEE: New York, NY, USA,2006; p. 43.
 Release, S. 3: Desmond Molecular Dynamics System, DE Shaw Research, New York, NY, 2017; Maestro-Desmond Interoperability Tools, Schrödinger: New York, NY, USA, 2009.

6. Phillips, J.C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R.D.; Kalé, L.; Schulten, K. Scalable molecular dynamics with NAMD. J. Comput. Chem. 2005, 26, 1781– 1802.

7. Kim, S.; Oshima, H.; Zhang, H.; Kern, N.R.; Re, S.; Lee, J.; Rous, B.; Sugita, Y.; Jiang, W.; Im, W. CHARMM-GUI free energy calculator for absolute and relative ligand solvation and binding free energy simulations. J. Chem. Theory Comput. 2020, 16, 7207–7218.